The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique

Health Policy and Planning

Volumn 20, Issue 1, 2005, Pages 50-59

  Griffiths, Ulla K ^a   Hutton, Guy ^b   Das Dores Pascoal, Eva ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Cost effectiveness; Costs; Economics; Hepatitis B; Modelling; Mozambique; Vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE;

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; HEPATITIS B; HUMAN; IMMUNIZATION; INFANT; MODEL; MORTALITY; MOZAMBIQUE; PRIMARY HEALTH CARE; QUALITY ADJUSTED LIFE YEAR; WORLD HEALTH ORGANIZATION;

CARRIER STATE; CHILD HEALTH SERVICES; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MODELS, ECONOMETRIC; MOZAMBIQUE; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 14644402448     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/czi006     Document Type: Article

References (40)

1. Aggarwal R. 2002. Inclusion of Hepatitis B vaccine in national immunization program in India: A review of economic analyses. Report undertaken for the World Health Organization Regional Office for South-East Asia.
2. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. The Lancet 2: 1129-33.
3. Beutels P. 1994. Economic evaluations of Hepatitis B immunization: a global review of recent studies 2000. Health Economics 10: 751-74.
4. Beutels P, Edmunds WJ, Antonanzas F et al. 2002. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20: 1-7.
5. Boisier P, Rabarijaona L, Piollet M, Roux JF, Zeller HG. 1996. Hepatitis B virus infection in general population in Madagascar: evidence for different epidemiological patterns in urban and in rural areas. Epidemiology and Infection 117: 133-7.
6. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. 2000. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 15: 825-41.
7. Decisioneering Inc. 2003. Crystal Ball 2000.2. Denver, Colorado.
8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. 1997. Methods for the economic evaluation of health care programmes. Second edition. Oxford: Oxford University Press.
9. Financing Task Force of the Global Alliance for Vaccines and Immunization. 2003. Guidelines for preparing a national immunization program financial sustainability plan, July 2003. Available from [http://www.gaviftf. org].
10. Gay N, Edmunds JW, Bah E, Nelson CB. 2001. Estimating the global burden of hepatitis B. Department of Vaccines and Biologicals. Geneva: World Health Organization. Unpublished work.
11. Gold MR, Siegel JE, Weinstein MC. 1996. Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
12. Goldstein ST, Zhou F, Hadler SC. 2003. The global reduction in Hepatitis B disease burden from vaccination. Abstract from International Viral Hepatitis Conference 2003, Sydney, and personal communication with S Goldstein, Center for Disease Control, Atlana, USA, October 2003.
13. Goodman C, Coleman P, Mills A. 2000. Economic analysis of malaria control in Sub-Saharan Africa. Geneva: Global Forum for Health Research.
14. Government of Mozambique. 2000. Proposal for support submitted to GAVI and The Fund. September 2000. Available from [http://www. vaccinealliance.org].
15. Hall A, Robertson R, Crivelli P et al. 1993. Cost-effectiveness of Hepatitis B vaccine in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 87: 333-6.
16. Harry TO, Bajani MD, Moses AE. 1994. Hepatitis B virus infection among blood donors and pregnant women in Maiduguri. Nigeria. East African Medical Journal 71: 596-7.
17. Jacobs B, Berege ZA, Schalula PJ, Klokke AH. 1994. Secondary school students: a safer blood donor population in an urban area with high HIV prevalence in East Africa. East African Medical Journal 71: 720-3.
18. Jager H, Goussard B, Kabeya CM et al. 1990. Voluntary blood donor recruitment: a strategy to reduce transmission of HIV-1, hepatitis-B and syphilis in Kinshasa, Zaire. Infusionstherapie 17: 224-6.
19. Jefferson T, Demicheli V. 1994. Is vaccination against Hepatitis B efficient: a review of world literature. Health Economics 3: 25-37.
20. Kane M, Clements J, Hu D. 1993. Hepatitis B. In: Jamison DT, Bobadilla J-L, Mosley WH, Measham AR (eds). Disease control priorities in developing countries. New York: Oxford University Press for the World Bank, 321-30.
21. Kew M, Marcus R, Geddes E. 1977. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. South African Medical Journal 51: 306-9.
22. Kiire C and African Regional Study Group. 1990. Hepatitis B infection in sub-Saharan Africa. Vaccine (supplement) 8: s107-12.
23. Kou UK. 2002. Guidelines for estimating costs of introducing new vaccines into the national immunization system. WHO/V&B/02.11. Geneva: World Health Organization, Department of Vaccines and Biologicals.
24. Lopez AD, Ahmad OB, Guillot M et al. 2002. World mortality in 2000. Life tables for 191 countries. Geneva: World Health Organization.
25. Madzime S, Adem M, Mahomed K et al. 1996. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, to 1997. Central African Journal of Medicine 45: 195-8.
26. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. 1990. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Archives of Internal Medicine 150: 1051-4.
27. Ministry of Health. 2002. Plano de Sustentabilidade Financeira do Programa Alargado de Vacinacao. Maputo: Mozambique Ministry of Health. Available from [http://www.vaccinealliance.org].
28. Murray CJL, Lopez AD. 1996a. Global health statistics. Geneva: World Health Organization.
29. Murray CJL, Lopez AD. 1996b. The global burden of disease. Geneva: World Health Organization.
30. PriceWaterhouseCoopers. 2002. Report on the immunization data quality audit (DQA) for the year 2001-Mozambique. Study undertaken for the Global Alliance for Vaccines and Immunization.
31. Sadykova D. 2002. Cost-effectiveness analysis of vaccination against Hepatitis B in Kahzakstan. Master of Public Health thesis. Jerusalem: Hadassah Hospital-Hebrew University School of Public Health.
32. Shepard DD, Walsh JA, Kleiau E, Stansfield S, Bhalotra S. 1995. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 13: 707-14.
33. UNICEF. 2004. Supply division, at [http://www.supply.unicef.dk], accessed 8 April 2004.
34. United Nations. 2001. World population prospects: The 2000 revision file 4: Births by major area, region, and country, 2001-2050. Estimates 2001-2050. POP/DB/WPP/Rev.2000/1/F5. New York: United Nations.
35. Whittle H, Jaffar S, Wansbrough M et al. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. British Medical Journal 325: 569.
36. WHO. 2000. Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. Department of Vaccines and Biologicals. WHO/V&B/00.36. Geneva: World Health Organization.
37. WHO. 2001a. Vaccine volume calculator: An aid for the introduction of new vaccines. Available at [http://www.who.int/vaccines-documents].
38. WHO. 2001b. Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents. WHO/V&B/01.31. Geneva: World Health Organization.
39. WHO. 2002a. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization.
40. WHO. 2002b. WHO, Vaccines and Biologicals. WHO vaccine-preventable diseases: Monitoring system. 2002 global summary. Geneva: World Health Organization.